The Cholesterol Test Market was valued at USD 6.35 billion in 2022 and is expected to reach USD 11.58 billion in 2030 and grow at a CAGR of 7.8% over the forecast period of 2023-2030. The Driving Forces of Market Harmony: Several key factors orchestrate the market's crescendo: Rising prevalence of cardiovascular diseases: With heart disease a leading cause of mortality...

According to the latest report by IMARC Group, titled “Companion Diagnostics Market Share: Global Industry Trends, Size, Growth, Opportunity and Forecast 2022-2027,” The global companion diagnostics market size reached US$ 5.0 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 11.7 Billion by 2027, exhibiting a growth rate (CAGR) of 14.78% during...

IMARC Group's report titled "Companion Diagnostics Market Report by Product & Service (Assays, Kits and Reagents, Software and Services), Technology (Immunohistochemistry (IHC), Polymerase Chain Reaction (PCR), In-situ Hybridization (ISH), Real-time PCR (RT-PCR), Gene Sequencing, and Others), Indication (Cancer, Neurological Diseases, Infectious Diseases, Cardiovascular Diseases, and...

According to a new report published by UnivDatos Markets Insights, the Companion Diagnostics Market is expected to grow at a CAGR of around 16% from 2021-2027. The analysis has been segmented into indication (breast cancer, lung cancer, colorectal cancer, gastric cancer, and others); technology (real-time-polymerase chain reactions, gene sequencing, fluorescence in situ hybridization, and...

According to a new report published by UnivDatos Markets Insights, the Companion Diagnostics Market is expected to grow at a CAGR of around 16% from 2021-2027. The analysis has been segmented into indication (breast cancer, lung cancer, colorectal cancer, gastric cancer, and others); technology (real-time-polymerase chain reactions, gene sequencing, fluorescence in situ hybridization, and...

Companion Diagnostics Market was estimated at USD 7.8 billion in 2022 and is poised to reach at 18.2 billion in 2030 anticipated to expand at a compound annual growth rate approx. CAGR of 11.2% for the forecast period of 2023-2030. This dynamic growth is driven by a powerful force: precision medicine. Demystifying the Diagnosis, Empowering Treatment: Companion diagnostics are specialized tests...

IMARC Group's report titled "Companion Diagnostics Market Report by Product & Service (Assays, Kits and Reagents, Software and Services), Technology (Immunohistochemistry (IHC), Polymerase Chain Reaction (PCR), In-situ Hybridization (ISH), Real-time PCR (RT-PCR), Gene Sequencing, and Others), Indication (Cancer, Neurological Diseases, Infectious Diseases, Cardiovascular Diseases, and...

The Companion Diagnostics Market in 2023 is US$ 6.83 billion, and is expected to reach US$ 16.22 billion by 2031 at a CAGR of 11.40%. FutureWise Research published a report that analyzes Companion Diagnostics Market trends to predict the market's growth. The report begins with a description of the business environment and explains the commercial summary of the chain structure. Based on the...

The companion diagnostics market is a rapidly evolving segment of the healthcare industry, driven by advancements in personalized medicine and the growing need for targeted therapies. Companion diagnostics (CDx) are essential tools that help identify the appropriate patients for specific treatments, enhancing therapeutic efficacy and minimizing adverse effects. As the healthcare landscape...

The global companion diagnostics market is growing at a significant CAGR of around 12.8% during the forecast period. Companion diagnostics is referred to as in-vitro diagnostic device or an imaging tool that is used as a companion to a certain class of a therapeutic drug, to determine its relevancy to a patient. Companion Diagnostics Market research report allows making important decision...